Deep Track reports 5.30% stake in Viridian Therapeutics

Viridian Therapeutics received a Schedule 13G disclosure reporting a 5,417,660-share position (5.30% of the class) held by Deep Track entities and David Kroin.

Rhea-AI Filing Summary

Viridian Therapeutics received a Schedule 13G disclosure reporting a 5,417,660-share position (5.30% of the class) held by Deep Track entities and David Kroin. The filing states the position reflects 102,206,571 shares outstanding as of February 20, 2026. The reporting persons indicate shared voting and dispositive power over the 5,417,660 shares; sole voting and dispositive power are reported as 0. The filing is a joint Schedule 13G by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and includes a parent/subsidiary attribution note naming Deep Track Capital, LP as the relevant entity.

Insights

Equity Ownership Analyst

Holders report a passive 5.30% stake via shared voting/dispositive power.

The Schedule 13G lists 5,417,660 shares beneficially owned, representing 5.30% of the class using the issuer's 102,206,571 share count as of February 20, 2026. The entries show shared voting and dispositive power and record sole powers as 0, consistent with a shared or advisory control structure.

Filing mechanics: this is a joint disclosure under Rule 13d-1(k) with signatures by David Kroin. Future changes in holdings or voting arrangements would appear in amendments to the 13G/13D series.

Corporate Governance Specialist

Disclosure signals coordinated reporting rather than an acquisition announcement.

The statement includes a parent/subsidiary attribution noting Deep Track Capital, LP as the relevant entity for control-person attribution. The filing records shared powers only, which commonly reflects nominee, fund, or joint-management arrangements rather than unilateral control.

Material governance effects depend on any future amendments or filings; the current Schedule 13G alone does not indicate changes to voting alignment or director nominations.

Key Figures

Beneficially owned shares: 5,417,660 shares Percent of class: 5.30% Shares outstanding used: 102,206,571 shares

3 metrics

Beneficially owned shares 5,417,660 shares Amount beneficially owned reported on Schedule 13G

Percent of class 5.30% Percent of common stock based on issuer share count

Shares outstanding used 102,206,571 shares Shares outstanding as of <date>February 20, 2026</date> per issuer 10-K

Key Terms

beneficially owned, shared voting power, Schedule 13G

3 terms

beneficially owned regulatory

"Amount beneficially owned: 5,417,660"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power corporate

"Shared Voting Power 5,417,660.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Schedule 13G regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did Deep Track report in VIRIDIAN THERAPEUTICS (VRDN)?

Deep Track and affiliated reporting persons reported beneficial ownership of 5,417,660 shares, representing 5.30% of Viridian's common stock using the issuer's share count of 102,206,571 as of February 20, 2026.

Who filed the Schedule 13G for VRDN and how were powers reported?

The Schedule 13G was filed jointly by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reporting shared voting and shared dispositive power over the 5,417,660 shares and 0 sole power.

Does this Schedule 13G indicate Deep Track controls Viridian (VRDN)?

The filing reports shared voting and dispositive power but does not assert sole control; it also designates Deep Track Capital, LP as the relevant entity for attribution, not an explicit control change or takeover.

What share count was used to calculate the 5.30% ownership in VRDN?

The percentage is calculated using the issuer-reported total of 102,206,571 shares outstanding as of February 20, 2026, which is cited in the filing and the issuer's 10-K.

Will this Schedule 13G trigger additional disclosure from Viridian?

A Schedule 13G itself is a beneficial ownership disclosure and does not by itself trigger issuer action; any issuer disclosures would depend on subsequent material events or amendments filed by the reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:17 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

VIRIDIAN THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

92790C104

(CUSIP Number)

05/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,417,660.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,417,660.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,417,660.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.30 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,417,660.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,417,660.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,417,660.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.30 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,417,660.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,417,660.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,417,660.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.30 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VIRIDIAN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 221 Crescent Street, Suite 103A, Waltham, MA 02453
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, $0.01 par value per share
(e)	CUSIP Number(s): 92790C104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,417,660
(b)	Percent of class: 5.30%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5,417,660
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 5,417,660
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	05/08/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	05/08/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	05/08/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of May 8, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 102,206,571 shares outstanding as of February 20, 2026, as reported by the issuer on its 10-K filed with the SEC on February 26, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 8, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin